急诊科高敏肌钙蛋白与传统肌钙蛋白HEART路径的心脏风险分层比较
该多中心前后队列研究于2021年1月1日至9月6日在16家Kaiser Permanente南加州医院开展,纳入17384例因胸痛就诊急诊科并接受基于传统肌钙蛋白或高敏肌钙蛋白的HEART路径风险分层的成年患者。高敏肌钙蛋白组30天内急性心肌梗死检出率高于传统肌钙蛋白组(5.8% vs 4.4%,P < .001),而30天全因死亡率无变化(0.3% vs 0.4%,P = .50)。高敏肌钙蛋白组急诊科内急性心肌梗死诊断率更高(4.6% vs 2.0%,P < .001),未在急诊科诊断者在30天内诊断的比例更低(1.2% vs 2.4%,P < .001)。高敏肌钙蛋白组入院、7天内负荷试验和30天内冠状动脉血运重建率均更低。作者认为,采用高敏肌钙蛋白的新HEART路径可能改善急性心肌梗死检出并减少资源使用。
要点
- 高敏肌钙蛋白组30天内急性心肌梗死检出率5.8%(288/4944),传统肌钙蛋白组4.4%(545/12440),P < .001。
- 高敏肌钙蛋白组急诊科内急性心肌梗死诊断率4.6%(228/4944),传统肌钙蛋白组2.0%(251/12440),P < .001。
- 未在急诊科诊断急性心肌梗死者中,高敏肌钙蛋白组30天内额外诊断1.2%(60例),传统肌钙蛋白组2.4%(294例),P < .001。
- 高敏肌钙蛋白组入院率12.2%(605例)低于传统肌钙蛋白组15.0%(1862例),P < .001。
- 两组30天全因死亡率无显著差异(0.3% vs 0.4%,P = .50)。
适用人群与场景
- 2021年1月1日至9月6日在16家Kaiser Permanente南加州医院急诊科就诊的成年胸痛患者,共17384例,中位年龄58岁(IQR 45-69岁),女性9767例(56.2%)。
研究设计与关键结果
- 研究设计:多中心前后队列研究,16家医院,纳入17384例急诊胸痛患者,比较高敏肌钙蛋白HEART路径(4944例,28.4%)与传统肌钙蛋白HEART路径(12440例,71.6%)的风险分层。
- 主要终点:30天内急性心肌梗死检出率高敏肌钙蛋白组5.8%(288例)vs 传统肌钙蛋白组4.4%(545例),P < .001。
- 急诊科内急性心肌梗死诊断率高敏肌钙蛋白组4.6%(228/4944)vs 传统肌钙蛋白组2.0%(251/12440),P < .001。
- 急诊科未诊断急性心肌梗死者中30天内诊断率高敏肌钙蛋白组1.2%(60例)vs 传统肌钙蛋白组2.4%(294例),P < .001。
- 30天全因死亡率高敏肌钙蛋白组0.3%(16例)vs 传统肌钙蛋白组0.4%(50例),P = .50。
- 入院率高敏肌钙蛋白组12.2%(605例)vs 传统肌钙蛋白组15.0%(1862例),P < .001;7天内负荷试验率10.2%(506例)vs 12.8%(1591例),P < .001;30天内冠状动脉血运重建率1.0%(51例)vs 2.0%(244例),P < .001。
证据类型、等级与局限
- 证据类型:多中心前后队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,采用高敏肌钙蛋白的新HEART路径可能改善急诊胸痛患者的急性心肌梗死检出并减少医疗资源使用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Patients presenting to the emergency department with chest pain are routinely risk stratified for major adverse cardiac events using the HEART (History, Electrocardiogram, Age, Risk factors, and Troponin) score pathway, which incorporates clinical features, risk factors, electrocardiography findings, and initial serum troponin testing. A new HEART pathway incorporating high-sensitivity troponin level may improve risk stratification among patients with possible acute myocardial infarction (AMI).
OBJECTIVE: To compare health outcomes and resource use among emergency department patients undergoing cardiac risk stratification with a HEART pathway using conventional vs high-sensitivity serum troponin.
DESIGN, SETTING, AND PARTICIPANTS: This multicenter pre-post cohort study was conducted between January 1 and September 6, 2021, at 16 Kaiser Permanente Southern California hospitals during uptake of a high-sensitivity serum troponin assay and included 17 384 adult patients who presented to an emergency department with chest pain and were risk stratified with a HEART pathway based on conventional troponin or high-sensitivity troponin.
EXPOSURES: A HEART pathway incorporating either conventional or high-sensitivity serum troponin was used to stratify study groups for risk of major adverse cardiac events within 30 days.
MAIN OUTCOMES AND MEASURES: The primary outcome was detection of AMI in the emergency department and within 30 days.
RESULTS: Of the 17 384 patients (median age, 58 years [IQR, 45-69 years]; 9767 women [56.2%]), 12 440 (71.6%) were risk stratified with a HEART pathway based on conventional troponin, and 4944 (28.4%) were risk stratified with a HEART pathway based on high-sensitivity troponin. Detection of AMI within 30 days was higher for the high-sensitivity troponin group than the conventional troponin group (288 [5.8%] vs 545 [4.4%]; P < .001), while the 30-day all-cause mortality rate was unchanged (16 [0.3%] vs 50 [0.4%]; P = .50). In the emergency department, 228 of 4944 patients (4.6%) in the high-sensitivity troponin group received a diagnosis of AMI compared with 251 of 12 440 patients (2.0%) in the conventional troponin group (P < .001). Among those who did not receive a diagnosis of AMI in the emergency department, an additional 60 patients (1.2%) in the high-sensitivity troponin group and 294 (2.4%) in the conventional troponin group (P < .001) received a diagnosis within 30 days. Patients in the high-sensitivity troponin group had lower rates of health care use compared with the conventional troponin group, including admission (605 [12.2%] vs 1862 [15.0%]; P < .001), stress testing within 7 days (506 [10.2%] vs 1591 [12.8%]; P < .001), and coronary revascularization within 30 days (51 [1.0%] vs 244 [2.0%]; P < .001).
CONCLUSIONS AND RELEVANCE: This multicenter pre-post cohort study suggests that a new HEART pathway incorporating high-sensitivity troponin may improve detection of AMI and decrease resource use among emergency department patients with chest pain.
参考来源
- Yore M, Sharp A, Wu YL, et al. Emergency Department Cardiac Risk Stratification With High-Sensitivity vs Conventional Troponin HEART Pathway. JAMA Netw Open. 2023. PMID: 38113042. doi:10.1001/jamanetworkopen.2023.48351
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。